This article is more than 5 years old. Information may no longer be current.

Novartis, Intellia expand collaboration for CRISPR/Cas9-based products

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Intellia Therapeutics and Novartis are expanding their cell therapy collaboration agreement to include the ex vivo development of therapies using certain ocular stem cells, according to a press release.

Novartis will be able to use these stem cells to develop CRISPR/Cas9-based products under the agreement. Intellia will receive a one-time payment of $10 million, as well as be eligible for success-based milestones and royalties.

In addition, Intellia will gain extended rights to Novartis’ lipid nanoparticle technology for genome editing applications, the release said.

“Genome editing enhancements made by CRISPR/Cas9 will enable the next generation of cell therapies. With our collaborator, Novartis, we are broadening the ex vivo application of our CRISPR/Cas9 technology from hematopoietic stem cells, or HSCs, to ocular stem cells,” John Leonard, MD, Intellia CEO and president, said in the release.